Judy Shaqfah
Overview
Explore the profile of Judy Shaqfah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
2
Citations
1
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaqfah J, Kang W, Gaudette F, Khalil M, Kwan C, Belliveau S, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2025 Jan;
PMID: 39841218
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the main treatment for motor symptoms of Parkinson's disease (PD). However, chronic use is associated with the development of complications such as L-DOPA-induced dyskinesia. We previously demonstrated...
2.
Kim E, Frouni I, Shaqfah J, Bedard D, Huot P
J Chem Neuroanat
. 2024 Apr;
138:102422.
PMID: 38657828
L-3,4-dihydroxyphenylalanine (L-DOPA) is the treatment of choice for Parkinson's disease (PD) motor symptoms, but its chronic use is hindered by complications such as dyskinesia. Pre-clinical studies discovered that activation of...
3.
Frouni I, Kim E, Shaqfah J, Bedard D, Kwan C, Belliveau S, et al.
Exp Brain Res
. 2024 Mar;
242(5):1203-1214.
PMID: 38526743
L-3,4-dihydroxyphenylalanine (L-DOPA) is the main treatment for Parkinson's disease (PD) but with long term administration, motor complications such as dyskinesia are induced. Glycine transporter 1 (GlyT1) inhibition was shown to...